Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Biological Characterization of TAK-901, an Investigational, Novel, Multitargeted Aurora B Kinase Inhibitor

28 Jan 2013

Abstract excerpt

Protein kinases Aurora A, B, and C play essential roles during mitosis and cell division, are frequently elevated in cancer, and represent attractive targets for therapeutic intervention. TAK-901 is an investigational, multitargeted Aurora B kinase inhibitor derived from a novel azacarboline kinase hinge-binder chemotype. TAK-901 exhibited time-dependent, tight-binding inhibition of Aurora B, but not Aurora A....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer-related Molecular Pathways
Share to Microtubule and mitosis dynamics
Share to Ubiquitin and proteasome pathways

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 23358665
DOI: 10.1158/1535-7163.mct-12-0657

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Biological Characterization of TAK-901, an Investigational, Novel, Multitargeted Aurora B Kinase InhibitorPMID 23358665Read ↗

An update on the pharmacokinetics and pharmacodynamics of alisertib, a selective Aurora kinase A inhibitorSemantic proximity Read ↗

Preclinical evaluation of AMG 900, a novel potent and highly selective pan-aurora kinase inhibitor with activity in taxane-resistant tumor cell lines.Semantic proximity Read ↗

A comprehensive review on role of Aurora kinase inhibitors (AKIs) in cancer therapeuticsSemantic proximity Read ↗

Aurora kinase inhibitors as anti-cancer therapySemantic proximity Read ↗

Aurora A–Selective Inhibitor LY3295668 Leads to Dominant Mitotic Arrest, Apoptosis in Cancer Cells, and Shows Potent Preclinical Antitumor EfficacySemantic proximity Read ↗

TAS-119, a novel selective Aurora A and TRK inhibitor, exhibits antitumor efficacy in preclinical models with deregulated activation of the Myc, β-Catenin, and TRK pathways.Semantic proximity Read ↗

Aurora kinase A in gastrointestinal cancers: time to targetSemantic proximity Read ↗

Aurora Kinases as Anticancer Drug TargetsSemantic proximity Read ↗

Aurora kinase inhibitors: Progress towards the clinicSemantic proximity Read ↗

PHA-680632, a novel Aurora kinase inhibitor with potent antitumoral activity.Semantic proximity Read ↗

Aurora Kinase Inhibitors - Rising Stars in Cancer Therapeutics?Semantic proximity Read ↗

Aurora Kinase B Inhibition: A Potential Therapeutic Strategy for CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.